证券代码：301139 证券简称：*ST 元道 公告编号：2026-055 元道通信股份有限公司 关于取消 2025 年年度股东会部分提案并增加临时提案暨 2025 年年 度股东会补充通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、原利润分配预案及股东会召开通知的情况 元道通信股份有限公司（以下简称"公司"）第四届董事会第十七次会议审议通过了 《关于<2025 年度利润分配预案>的议案》，公司 2025 年度的利润分配预案为：以公司现有 总股本 121,580,800 股为基数，向全体在册股东按每 10 股派发现金股利 0.073 元（含税）， 剩余未分配利润结转以后年度分配，本年度不送红股，不进行资本公积金转增股本。并同 意提交 2025 年年度股东会审议。具体详见公司于 2026 年 4 月 29 日披露于巨潮资讯网的 《第四届董事会第十七次会议决议公告》《关于召开 2025 年年度股东会的通知》。 二、取消提案的情况 现因公司近期资金账户冻结的问题，预计无法按期完成本次权益分派，2026 年 6 月 24 日第四届董事会第十八次会议审议通 ...

证券代码：301139 证券简称：*ST元道 公告编号：2026-054 元道通信股份有限公司 第四届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 公司第四届董事会第十七次会议审议通过了《关于<2025 年度利润分配预 案>的议案》，公司 2025 年度的利润分配预案为：以公司现有总股本 121,580,800 股为基数，向全体在册股东按每 10 股派发现金股利 0.073 元（含税），剩余未 分配利润结转以后年度分配，本年度不送红股，不进行资本公积金转增股本。 并同意提交 2025 年年度股东会审议。 现因公司近期资金账户冻结的问题，预计无法按期完成本次权益分派，经 公司管理层决定，取消原拟提交公司 2025 年年度股东会审议的《关于<2025 年 度利润分配预案>的议案》。 表决结果：7 票同意，0 票反对，0 票弃权。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的相关公 告。 （二）审议通过《关于<2025 年度利润分配预案>的议案》 公司 2025 年度的利润分配预案 ...

J P M O R G A N Economic Research 24 June 2026 Australia: CPI tracking further below SoMP forecasts May's monthly CPI reading was below our sub-consensus forecast at -0.7%m/m (JPM: -0.5%m/m, consensus: -0.4%m/m), or 4.0%oya. Trimmed mean was a firm +0.4% on the month, though, with two of three months in hand, the implied %3m/3m rate on core is still sticking at 0.8%q/q and gradually decelerating, with measures of breadth also well-capped. This is lower than the %m/m core prints from late 2025, despite what ...

Flash | 23 Jun 2026 23:32:27 ET │ 11 pages The A2 Milk Company Ltd (A2M.AX) 6.18 rankings look reasonable in current circumstances CITI'S TAKE We've come across Tmall Global 6.18 pre-sales rankings for the baby category and we thought a2's rank of #5 was positive given the ranking has fallen only 2 places from #3 in the 2025 Double 11 festival, despite a2's supply constraints and market access challenges. We also think the risk of longer-term brand damage appears to be minimal as these 6.18 pre-sales also o ...

June 24, 2026 03:47 AM GMT BoJ Watch | Japan M Update Comment Calling for "a Rate Hike with Intervals of a Few Months ": June MPM Summary of Opinions Key Takeaways In the June Summary of Opinions, overall, concerns over significant downside risks to the economy have receded, while many members expressed awareness of upside risks to prices. As a whole, the content did not materially alter our assessment presented in the post-meeting review following the June Monetary Policy Meeting (BoJ Watch & Macro Strateg ...

Antero J.P. Morgan Natural Resources Conference Takeaways J P M O R G A N North America Equity Research 23 June 2026 Oil & Gas Exploration & Production Arun Jayaram AC (1-212) 622-8541 arun.jayaram@jpmchase.com Pankaj Bhatter, CFA (1-212) 622-3795 pankaj.bhatter@jpmchase.com Jack Jerusalmi We caught up with AR on the sidelines of our J.P. Morgan Natural Resources Conference today. The AR senior management team, including Michael Kennedy (CEO & President), Brendan Krueger (CFO), and Dan Katzenberg (Vice Pres ...

Net Takeaway: Fresh off a 2026 capex raise and building into an increasingly anticipated plan update next earnings call, Plains discussed increased producer activity driving renewed Permian and Canadian gathering and brownfield long haul takeaway expansions. We see a phased expansion on Cactus III alongside Rainbow and/or Rangeland growth projects as likely, with finer details provided alongside 2Q results. After recounting 7% crude oil segment growth over the past five years, PAA appeared confident in stea ...

June 24, 2026 03:02 AM GMT argenx SE | North America Autoimmune Myositis: Don't throw the baby out with the bath water | What's Changed | | | | --- | --- | --- | | argenx SE (ARGX.O) | From | To | | Price Target | $1,170.00 | $1,180.00 | ARGX negative reaction on the separation of DM & IMNM programs is overdone. We think Street underestimates the magnitude of the myositis opportunity. The R&D Day reframed ALKIVIA ahead of 3Q26 data: less a pooled myositis story, more IMNM first with DM as a separate upside ...

SERENA-4 may still hit, but will it matter? AstraZeneca Plc | Europe June 24, 2026 03:30 AM GMT Roche's persevERA miss resets the SERENA-4 bar into H2'26. De novo diluted the benefit, while >12m relapse looked better. SERENA-4 is larger & later relapse-enriched, but mix risk remains. A PFS HR 0.87-88 may be enough statistically, but~ $3bn camizestrant cons. and the ~$10bn 1L SERD market may need stronger PFS/OS. Key Takeaways Roche's persevERA miss resets the bar for 1L oral SERDs ahead of AZN's SERENA-4 pi ...

货币政策与市场动态 - 日本银行在6月会议上确认了鹰派倾向，支持继续加息，预计下次加息将在10月进行[1] - 会议中几乎所有成员指出通胀压力在增强，尤其是生产者价格的上升可能会影响消费者通胀[2] - 有成员提到，人工智能相关需求的全球扩张正在加大价格压力，可能导致更广泛的价格上涨[2] - 货币政策讨论偏向鹰派，部分成员建议尽快将政策利率接近中性利率，认为中性利率大约在2%[2] - 尽管存在反对意见，但持续的通胀风险和市场压力将支持日本银行在10月加息的预期[4] 市场参与与合规 - J.P. Morgan在墨西哥证券市场的参与包括作为墨西哥证券交易所和机构证券交易所的成员[29] - J.P. Morgan在新西兰仅向批发客户发行和分发材料，符合2013年金融市场行为法的定义[30] - J.P. Morgan在菲律宾证券交易所的参与由菲律宾证券公司监管，确保合规性[31] - 新加坡的材料仅向合格投资者、专家投资者和机构投资者发行，符合证券与期货法的规定[32] - J.P. Morgan在南非的业务受到金融服务行为管理局的监管，确保市场合规[33] - 台湾的证券材料由J.P. Morgan证券（台湾）有限公司发行，受台湾证券期货局监管[34] - 泰国的材料由J.P. Morgan证券（泰国）有限公司发行，受泰国财政部和证券交易委员会监管[35] - 英国的研究由J.P. Morgan证券有限公司生产，符合金融服务与市场法的相关规定[36] - 美国的材料由J.P. Morgan证券有限责任公司分发，确保符合美国证券市场的监管要求[37] - J.P. Morgan对材料的准确性和完整性不作任何保证，投资者需自行判断和决策[38]